The Effects of Sacubitril/Valsartan on Serum Levels of Cystatin C and Galectin-3 in Old Hypertensive Patients of Heart Failure with Preserved Ejection Fraction
To investigate the effects of sacubitril/valsartan on serum levels of cystatin C and galectin-3 in old hypertensive patientsof heart failure with preserved ejection fraction,hypertensive patients of heart failure with preserved ejection fraction were enrolled between January 2020 and October 2022.A total of 126 patients were divided into sacubitril/valsartan users and valsartan users,and received treatment for 3 months.The changes of 24 h blood pressure and cardiac function,as well as the serum levels of cystatin C and galectin-3 were investigated before and after treatment.The results showed that the 24 h systolic blood pressure and 24 h dias-tolic blood pressure were decreased after treatment in both of groups(P＜0.05).Cardiac function as displayed by left ventricular ejection fraction was increased by both sacubitril/valsartan and valsartan treatment(P＜0.01).Moreover,serum levels of cystatin C and galectin-3 were also decreased after treatment(P＜0.05).Importantly,patients in the sacubitril/valsartan group had lower 24 h systolic blood pressure and 24 h diastolic blood pressure as well as higher left ventricular ejection fraction than those in the valsartan group(P＜0.05).In addition,the serum levels of cystatin C and galectin-3 were also lower in the sacubitril/valsartan group than in the valsartan group after treatment.In conclusion,the results indicate that the use of sacubitril/valsartan could significantly improve cardiac dysfunction and cardiac remodeling accompanied by effectively controlling the blood pressure in old hypertensive patients of heart failure with preserved ejection fraction.Further prospective multicenter studies will be needed to confirm the effects of sacubi-tril/valsartan on the prognosis of lower risk of hypertensive patients of heart failure with preserved ejection fraction.
Sacubitril/ValsartanHypertensionHeart failure with preserved ejection fractionCystatin CGalectin-3Cardiac remodeling
NETL
NSTL
万方数据
